Your browser doesn't support javascript.
loading
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías, Juan P; Auerbach, Pernille; Bajaj, Harpreet S; Fukushima, Yasushi; Lingvay, Ildiko; Macura, Stanislava; Søndergaard, Anette L; Tankova, Tsvetalina I; Tentolouris, Nikolaos; Buse, John B.
Afiliação
  • Frías JP; Clinical Research, National Research Institute, Los Angeles, CA, USA. Electronic address: juan.frias@nritrials.com.
  • Auerbach P; Novo Nordisk, Søborg, Denmark.
  • Bajaj HS; LMC Diabetes and Endocrinology, Brampton, ON, Canada.
  • Fukushima Y; Fukuwa Clinic, Tokyo, Japan.
  • Lingvay I; Department of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Macura S; Novo Nordisk, Søborg, Denmark.
  • Søndergaard AL; Novo Nordisk, Søborg, Denmark.
  • Tankova TI; Department of Endocrinology, Medical University of Sofia, Sofia, Bulgaria.
  • Tentolouris N; Diabetes Centre, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
  • Buse JB; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Lancet Diabetes Endocrinol ; 9(9): 563-574, 2021 09.
Article em En | MEDLINE | ID: mdl-34293304

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Peptídeos Semelhantes ao Glucagon / Hipoglicemiantes Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Peptídeos Semelhantes ao Glucagon / Hipoglicemiantes Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article